# Safety and Efficacy Study of Treatment With Single Doses of CHF 4226 pMDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT00782535** · PHASE2 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 20 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** CHF 4226 pMDI
- **DRUG:** CHF 4226 pMDI
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00782535
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2019-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00782535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00782535, "Safety and Efficacy Study of Treatment With Single Doses of CHF 4226 pMDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00782535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*